Cargando…
Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer
Two types of prognostic signatures for predicting recurrent risk of ER+ breast cancer patients have been developed: one type for patients accepting surgery only and another type for patients receiving post-operative tamoxifen therapy. However, the first type of signature cannot distinguish high-risk...
Autores principales: | Cai, Hao, Li, Xiangyu, Li, Jing, Ao, Lu, Yan, Haidan, Tong, Mengsha, Guan, Qingzhou, Li, Mengyao, Guo, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792578/ https://www.ncbi.nlm.nih.gov/pubmed/26527319 |
Ejemplares similares
-
An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection
por: Ao, Lu, et al.
Publicado: (2016) -
Identification of reproducible drug-resistance-related dysregulated genes in small-scale cancer cell line experiments
por: Ao, Lu, et al.
Publicado: (2015) -
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups
por: Li, Xiangyu, et al.
Publicado: (2016) -
Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature
por: Guan, Qingzhou, et al.
Publicado: (2020) -
Differential expression analysis for individual cancer samples based on robust within-sample relative gene expression orderings across multiple profiling platforms
por: Guan, Qingzhou, et al.
Publicado: (2016)